Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
William J. Chiou, Sonia M. de Morais, Ryota Kikuchi, Richard L. Voorman, Xiaofeng Li & Daniel A. J. Bow. (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:3, pages 276-282.
Read now
Read now
Tom De Bruyn, Sagnik Chatterjee, Sarinj Fattah, Janneke Keemink, Johan Nicolaï, Patrick Augustijns & Pieter Annaert. (2013) Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism & Toxicology 9:5, pages 589-616.
Read now
Read now
Articles from other publishers (24)
Sadhana Kumbhar, Manish Musale & Anas Jamsa. (2024) Bilirubin metabolism: delving into the cellular and molecular mechanisms to predict complications. The Egyptian Journal of Internal Medicine 36:1.
Crossref
Crossref
Yanhong Gao, Huacheng Deng, Yuying Zhao, Mei Li, Liping Wang & Yujuan Zhang. (2024) Gene Expression of Abcc2 and Its Regulation by Chicken Xenobiotic Receptor. Toxics 12:1, pages 55.
Crossref
Crossref
Hussein Zaitoon, Morya Shnaider, Irit Shoris, Hadel Khalil, Arieh Riskin & Ayala Gover. (2023) Intrapartum Maternal Prophylactic Antimicrobial Treatment and Neonatal Jaundice. Clinical Pediatrics 62:12, pages 1562-1567.
Crossref
Crossref
Zon-Min Lee, Ling-Sai Chang, Kuang-Che Kuo, Meng-Chiao Lin & Hong-Ren Yu. (2023) Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants. Children 10:6, pages 926.
Crossref
Crossref
Zon-Min Lee, Yao-Hsu Yang, Ling-Sai Chang, Chih-Cheng Chen, Hong-Ren Yu & Kuang-Che Kuo. (2022) Increased Total Serum Bilirubin Level Post-Ibuprofen Use Is Inversely Correlated with Neonates’ Body Weight. Children 9:8, pages 1184.
Crossref
Crossref
Morvarid Zarif-Yeganeh & Mona Kargar. (2021) Comparison of the effect of different methods of cyclosporine infusion on transplant-related outcomes in allogeneic transplant recipients. Journal of Oncology Pharmacy Practice 27:3, pages 778-779.
Crossref
Crossref
Péter Tátrai & Péter Krajcsi. (2020) Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing. Pharmaceutics 12:8, pages 755.
Crossref
Crossref
David Busse, Sara Leandersson, Sara Amberntsson, Malin Darnell & Constanze Hilgendorf. (2020) Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation. Journal of Pharmaceutical Sciences 109:7, pages 2309-2320.
Crossref
Crossref
Kimberly S. Collins, Ingrid F. Metzger, Brandon T. Gufford, Jessica B. Lu, Elizabeth B. Medeiros, Victoria M. Pratt, Todd C. Skaar & Zeruesenay Desta. (2020) Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers. Drug Metabolism and Disposition 48:3, pages 169-175.
Crossref
Crossref
Coralea Stephanou, Stella Tamana, Anna Minaidou, Panayiota Papasavva, Marina Kleanthous & Petros Kountouris. (2019) Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies. Journal of Clinical Medicine 8:11, pages 1927.
Crossref
Crossref
Hisham Qosa, Brittany R. Avaritt, Neil R. Hartman & Donna A. Volpe. (2018) In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemotherapy and Pharmacology 82:5, pages 795-802.
Crossref
Crossref
Jiping Fu, Christopher Becker, Li Cao, Michael Capparelli, Regis Denay, Roger Fujimoto, Yu Gai, Zhaobo Gao, Christian Guenat, Subramanian Karur, Hongyong Kim, Weikuan Li, Xiaolin Li, Wei Li, Thomas Lochmann, Amy Lu, Peichao Lu, Alexandre Luneau, Nicole Meier, Wosenu Mergo, Simon Ng, David Parker, Yunshan Peng, Bernard Riss, Alexey Rivkin, Silvio Roggo, Harald Schroeder, Friedrich Schuerch, Robert L. Simmons, Feng Sun, Zachary K. Sweeney, Meiliana Tjandra, Michael Wang, Ruidong Wang, Andrew H. Weiss, Nicolas Wenger, Quanbing Wu, Xin Xiong, Su Xu, Wenjian Xu, Aregahegn Yifru, Jibin Zhao, Jianguang Zhou, Christian Zürcher & Fabrice Gallou. (2018) Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency. Bioorganic & Medicinal Chemistry 26:4, pages 957-969.
Crossref
Crossref
Young Hee Choi, Chang Ho Lee, Myong Suk Ko, Hyun Joo Han & Sang Geon Kim. (2017) Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis. Toxicological Research 33:4, pages 343-350.
Crossref
Crossref
Ricardo ZwirtesPremkumar NarasimhanMegan M. Wind-RotoloDong XuMatthew W. HruskaNarendra KishnaniElizabeth M. ColstonSubasree Srinivasan. (2016) Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation. Journal of Interferon & Cytokine Research 36:11, pages 644-651.
Crossref
Crossref
Rucha S. Sane, Gerhard G. Steinmann, Qihong Huang, Yongmei Li, Lalitha Podila, Kirsten Mease, Stephen Olson, Mitchell E. Taub, Jerry O. Stern, Gerhard Nehmiz, Wulf O. Böcher, Tarik Asselah & Donald Tweedie. (2014) Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients. Journal of Pharmacology and Experimental Therapeutics 351:2, pages 403-412.
Crossref
Crossref
Jiping Fu, Meiliana Tjandra, Christopher Becker, Dallas Bednarczyk, Michael Capparelli, Robert Elling, Imad Hanna, Roger Fujimoto, Markus Furegati, Subramanian Karur, Theresa Kasprzyk, Mark Knapp, Kwan Leung, Xiaolin Li, Peichao Lu, Wosenu Mergo, Charlotte Miault, Simon Ng, David Parker, Yunshan Peng, Silvio Roggo, Alexey Rivkin, Robert L. Simmons, Michael Wang, Brigitte Wiedmann, Andrew H. Weiss, Linda Xiao, Lili Xie, Wenjian Xu, Aregahegn Yifru, Shengtian Yang, Bo Zhou & Zachary K. Sweeney. (2014) Potent Nonimmunosuppressive Cyclophilin Inhibitors With Improved Pharmaceutical Properties and Decreased Transporter Inhibition. Journal of Medicinal Chemistry 57:20, pages 8503-8516.
Crossref
Crossref
Petra Thulin, Gunnar Nordahl, Marcus Gry, Getnet Yimer, Eleni Aklillu, Eyasu Makonnen, Getachew Aderaye, Lars Lindquist, C. Mikael Mattsson, Björn Ekblom, Daniel J. Antoine, B. Kevin Park, Stig Linder, Alison H. Harrill, Paul B. Watkins, Björn Glinghammar & Ina Schuppe‐Koistinen. (2013)
Keratin‐18 and micro
RNA
‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts
. Liver International 34:3, pages 367-378.
Crossref
Crossref
Jose L. Ulloa, Simone Stahl, James Yates, Neil Woodhouse, J. Gerry Kenna, Huw B. Jones, John C. Waterton & Paul D. Hockings. (2013) Assessment of gadoxetate DCE‐MRI as a biomarker of hepatobiliary transporter inhibition. NMR in Biomedicine 26:10, pages 1258-1270.
Crossref
Crossref
Alberto Corsini & Michele Bortolini. (2013) Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport. The Journal of Clinical Pharmacology 53:5, pages 463-474.
Crossref
Crossref
Bj�rn Glinghammar. (2012) Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. International Journal of Molecular Medicine.
Crossref
Crossref
Dilek Iusuf, Evita van de Steeg & Alfred H. Schinkel. (2012) Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends in Pharmacological Sciences 33:2, pages 100-108.
Crossref
Crossref
Sammy Pak-lam Chen, Wing-tat Poon, Chloe Miu Mak, Ching-wan Lam, Yok-lam Kwong, Albert Yan-wo Chan & Sidney Tam. (2011) Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia. Pathology 43:3, pages 273-274.
Crossref
Crossref
Min Kyoung Kim, Hee Soon Cho, Young Kyung Bae, Kyung Hee Lee, Hae-Sun Chung, Soo-Youn Lee & Myung Soo Hyun. (2009) Nilotinib-induced hyperbilirubinemia: Is it a negligible adverse event?. Leukemia Research 33:9, pages e159-e161.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:4.
Crossref
Crossref